NewslettersMammary Cell NewsMYC Is a Clinically Significant Driver of mTOR Inhibitor Resistance in Breast CancerBy Bob - August 31, 20230229Researchers showed that MYC activation drove resistance to mTOR inhibitors in breast cancer. MYC status was significantly associated with poor response to everolimus therapy in metastatic breast cancer patients.[Journal of Experimental Medicine]Full Article